Molecular Partners AG (0QXX) Price & Analysis
0QXX Stock Chart & Stats
- Day’s Range
- CHF 3.01 - CHF 3.01
- 52-Week Range
- CHF 2.88 - CHF 3.94
- Previous Close
- CHF 3.17
- Volume
- 2,319
- Average Volume (3M)
- 295
- Market Cap
- CHF 116.68M
- Enterprise Value
- CHF 55.01M
- Total Cash (Recent Filing)
- CHF 57.49M
- Total Debt (Recent Filing)
- CHF 2.74M
- Price to Earnings (P/E)
- ―
- Beta
- 0.96
- Next Earnings
- Mar 05, 2027
- EPS Estimate
- -0.35
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low leverage reduces the immediate burden of interest and debt repayment, preserving financial flexibility compared with a highly indebted biotechnology company. This provides a stabilizing balance-sheet feature while the company funds clinical development and seeks future partnering income.
Proprietary DARPin Platform
A proprietary DARPin discovery platform gives Molecular Partners a defined technological foundation across oncology and other therapeutic areas. If development programs progress, the platform can support multiple candidates and partnering opportunities rather than relying on a single asset.
Moderating Cash Burn
The reduction in free-cash-flow burn is a modest improvement in cash efficiency and could extend the period available for advancing programs. It does not solve the funding challenge, but sustained moderation would improve planning flexibility while clinical and partnering activities continue.
Bears Say
Revenue Collapse
The collapse to no reported revenue removes a current commercial income base and leaves results highly dependent on the timing of partnership-related payments. Without a return to recurring revenue, funding research and clinical development remains difficult to support internally.
Recurring Net Losses
Persistent large net losses show that the present operating model is not self-funding and has limited earnings visibility. Continued losses can consume capital needed for development, increase reliance on external financing or transactions, and make future profitability dependent on successful program outcomes.
Sustained Cash Burn And Shrinking Equity
Ongoing operating and free-cash-flow deficits are eroding the balance-sheet resources available to support the pipeline. The substantial decline in equity indicates that losses have already reduced financial capacity, increasing the importance of future funding or partnership proceeds.
Molecular Partners AG News
0QXX FAQ
What was Molecular Partners AG’s price range in the past 12 months?
What is Molecular Partners AG’s market cap?
When is Molecular Partners AG’s upcoming earnings report date?
How were Molecular Partners AG’s earnings last quarter?
Is Molecular Partners AG overvalued?
Does Molecular Partners AG pay dividends?
What is Molecular Partners AG’s EPS estimate?
How many shares outstanding does Molecular Partners AG have?
What happened to Molecular Partners AG’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Molecular Partners AG?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Molecular Partners AG
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Patrick Amstutz
- Employees
- 134
- Website
- www.molecularpartners.com
- Address
- Wagistrasse 14, Schlieren, ZH, 8952, CH
Molecular Partners AG (0QXX) Earnings & Revenues
0QXX Earnings Call
Earnings Call SentimentPositive
Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.
View all GB:0QXX earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |